Obinutuzumab
- Generic Name
- Obinutuzumab
- Brand Names
- Gazyva, Gazyvaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 949142-50-1
- Unique Ingredient Identifier
- O43472U9X8
- Background
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Le...
- Indication
Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
- Associated Conditions
- Refractory Follicular Lymphoma, Previously untreated Chronic lymphocytic leukemia
- Associated Therapies
- -
A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 114
- Registration Number
- NCT02600897
- Locations
- 🇬🇧
Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, United Kingdom
🇬🇧Maidstone & Tonbridge Wells Hospital; Kent Oncology Center, Maidstone, United Kingdom
🇬🇧Barking, Havering and Redbridge University Hospitals NHS Trust - Queen's Hospital, Romford, United Kingdom
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 91
- Registration Number
- NCT02596971
- Locations
- 🇦🇺
Concord Repatriation General Hospital; Haematology, Sydney, New South Wales, Australia
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Oncology Associates of Oregon, P.C.; Willamette Valley Cancer Institute, Springfield, Oregon, United States
A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation
- Conditions
- Interventions
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT02586051
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸UCSF, San Francisco, California, United States
🇺🇸Mayo Clinic - Minnesota, Rochester, Minnesota, United States
BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 119
- Registration Number
- NCT02569476
- Locations
- 🇺🇸
Florida Cancer Specialists Fort Myers, Fort Myers, Florida, United States
🇺🇸Florida Cancer Specialists East, West Palm Beach, Florida, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)
- Conditions
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 126
- Registration Number
- NCT02550652
- Locations
- 🇺🇸
Emory Uni ; Division of Rheumatology, Atlanta, Georgia, United States
🇺🇸Univ of California, San Diego, La Jolla, California, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 54
- Registration Number
- NCT02537613
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-08-20
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 59
- Registration Number
- NCT02529852
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
- Conditions
- Interventions
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 535
- Registration Number
- NCT02475681
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 203
- Registration Number
- NCT02457598
- Locations
- 🇬🇧
Cardiff and Vale Health Board, Clinical Research Facility, Cardiff, United Kingdom
🇺🇸Indiana University Health Goshen Center for Cancer Care, Goshen, Indiana, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 66
- Registration Number
- NCT02453087
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸New York University Cancer Cen, New York, New York, United States
🇺🇸Medical Center of Aurora; Rocky Mountain Cancer Centers, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.